Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-12

AUTHORS

Yun Hou, Hua-qing Wang, Yi Ba

ABSTRACT

This study was conducted to evaluate the efficacy and safety of Rituximab, Gemcitabine, Cisplatin, and Dexamethasone (R-GDP) in relapsed or refractory aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). Treatments consisted of rituximab 375 mg/m2, i.v. on day 1; gemcitabine 1,000 mg/m2, i.v. on days 1 and 8, dexamethasone 40 mg i.v. on days 1-4, and cisplatin 25 mg/m2 i.v. on days 1-3, every 21 days. The primary end-points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. Eligible patients could then proceed to high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) or receive up to six treatment cycles. From January 2005 to December 2010, 50 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory aggressive B-cell NHL, including diffuse large B-cell lymphoma (n=30) and follicular lymphoma grade 3b (n=20). The median follow-up time was 42 months (range, 12-70). After two cycles, the overall response rate was 72.0%, with a CR/CRu rate of 56%. The 2-year OS and PFS of all patients were 70.0 and 48.0%, respectively. Grade III-IV neutropenia and thrombocytopenia occurred in 34 and 40% of patients, respectively. Twenty-one patients (42%) proceeded to ASCT. Higher International Prognostic Index and refractory disease were independently associated with worse survival and progression-free survival. R-GDP chemotherapy in patients with refractory or relapsed aggressive B-Cell NHL was effective as a salvage therapy and helpful for HDC/ASCT. More... »

PAGES

2409-2416

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2

DOI

http://dx.doi.org/10.1007/s12032-012-0211-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048672161

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22476761


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Lymphoma department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China", 
            "Sino-US Center for Lymphoma and Leukemia, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hou", 
        "givenName": "Yun", 
        "id": "sg:person.0772057424.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772057424.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Lymphoma department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China", 
            "Sino-US Center for Lymphoma and Leukemia, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hua-qing", 
        "id": "sg:person.01372344523.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Digestive Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ba", 
        "givenName": "Yi", 
        "id": "sg:person.0601034665.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601034665.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1008294725992", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000992968", 
          "https://doi.org/10.1023/a:1008294725992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.2003.04226.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010001288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020799712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3904/kjim.2009.24.1.37", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029979747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3904/kjim.2009.24.1.37", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029979747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030304185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-08-3175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033024465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/clml.2010.n.055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034335280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-010-0666-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041242014", 
          "https://doi.org/10.1007/s12185-010-0666-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-010-0666-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041242014", 
          "https://doi.org/10.1007/s12185-010-0666-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000077995", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042104091"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-08-108415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052256184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.12.3786", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074556142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.21.3633", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074719574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083106286", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347691", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "This study was conducted to evaluate the efficacy and safety of Rituximab, Gemcitabine, Cisplatin, and Dexamethasone (R-GDP) in relapsed or refractory aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). Treatments consisted of rituximab 375 mg/m2, i.v. on day 1; gemcitabine 1,000 mg/m2, i.v. on days 1 and 8, dexamethasone 40 mg i.v. on days 1-4, and cisplatin 25 mg/m2 i.v. on days 1-3, every 21 days. The primary end-points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. Eligible patients could then proceed to high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) or receive up to six treatment cycles. From January 2005 to December 2010, 50 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory aggressive B-cell NHL, including diffuse large B-cell lymphoma (n=30) and follicular lymphoma grade 3b (n=20). The median follow-up time was 42 months (range, 12-70). After two cycles, the overall response rate was 72.0%, with a CR/CRu rate of 56%. The 2-year OS and PFS of all patients were 70.0 and 48.0%, respectively. Grade III-IV neutropenia and thrombocytopenia occurred in 34 and 40% of patients, respectively. Twenty-one patients (42%) proceeded to ASCT. Higher International Prognostic Index and refractory disease were independently associated with worse survival and progression-free survival. R-GDP chemotherapy in patients with refractory or relapsed aggressive B-Cell NHL was effective as a salvage therapy and helpful for HDC/ASCT.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-012-0211-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma", 
    "pagination": "2409-2416", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e7dd5c28e14ce6994240f0579d320f4c64ba1715c07a3bf6a4e0983c4ed7906f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22476761"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-012-0211-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048672161"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-012-0211-2", 
      "https://app.dimensions.ai/details/publication/pub.1048672161"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000524.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12032-012-0211-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0211-2'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      21 PREDICATES      59 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-012-0211-2 schema:about N094db75dbd744cd7963bd14556baf036
2 N2e0b46cb572f45c2bc7395b6f82acbc7
3 N38282c13a6bd42888e4750715b3a0866
4 N4ba110f342b74a33ae04d82c97954ab8
5 N4dabc9bc3bc44e36b5f78036eb5f08c2
6 N4ed7b348d9c14968a107ce77018e8811
7 N55638aab395e42aab9eabfcfd3321a02
8 N61b510cdee58488dad5ce7b1aecfb115
9 N94e0eaaf70d04d4792c2a46ddc98722b
10 N9dad7e421b2a415cbb1883a653e83f1d
11 Na836484be1ef4971ba571bfe66a89066
12 Nb09feada92ec47efaab454740bd13888
13 Nf23216c1e99c4151ab37a308540bbbfc
14 Nfa70c05531b24ab0a2ef7d3059a2a206
15 Nfc8825c4593041f8a866946d38fd49c3
16 Nff6bb8f557494191be897ea25ee70483
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Ndb5ca55c8f1547caa8040be388387905
20 schema:citation sg:pub.10.1007/s12185-010-0666-x
21 sg:pub.10.1023/a:1008294725992
22 https://app.dimensions.ai/details/publication/pub.1083106286
23 https://app.dimensions.ai/details/publication/pub.1083347691
24 https://doi.org/10.1046/j.1365-2141.2003.04226.x
25 https://doi.org/10.1093/annonc/mdh093
26 https://doi.org/10.1093/annonc/mdm133
27 https://doi.org/10.1159/000077995
28 https://doi.org/10.1182/blood-2004-08-3175
29 https://doi.org/10.1182/blood-2007-08-108415
30 https://doi.org/10.1200/jco.1999.17.12.3786
31 https://doi.org/10.1200/jco.2000.18.21.3633
32 https://doi.org/10.3816/clml.2010.n.055
33 https://doi.org/10.3904/kjim.2009.24.1.37
34 schema:datePublished 2012-12
35 schema:datePublishedReg 2012-12-01
36 schema:description This study was conducted to evaluate the efficacy and safety of Rituximab, Gemcitabine, Cisplatin, and Dexamethasone (R-GDP) in relapsed or refractory aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). Treatments consisted of rituximab 375 mg/m2, i.v. on day 1; gemcitabine 1,000 mg/m2, i.v. on days 1 and 8, dexamethasone 40 mg i.v. on days 1-4, and cisplatin 25 mg/m2 i.v. on days 1-3, every 21 days. The primary end-points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. Eligible patients could then proceed to high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) or receive up to six treatment cycles. From January 2005 to December 2010, 50 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory aggressive B-cell NHL, including diffuse large B-cell lymphoma (n=30) and follicular lymphoma grade 3b (n=20). The median follow-up time was 42 months (range, 12-70). After two cycles, the overall response rate was 72.0%, with a CR/CRu rate of 56%. The 2-year OS and PFS of all patients were 70.0 and 48.0%, respectively. Grade III-IV neutropenia and thrombocytopenia occurred in 34 and 40% of patients, respectively. Twenty-one patients (42%) proceeded to ASCT. Higher International Prognostic Index and refractory disease were independently associated with worse survival and progression-free survival. R-GDP chemotherapy in patients with refractory or relapsed aggressive B-Cell NHL was effective as a salvage therapy and helpful for HDC/ASCT.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N08429036bef2482490ed98718b67df3a
41 N912e9577004b442c88a48f8dc0e82aa4
42 sg:journal.1094524
43 schema:name Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
44 schema:pagination 2409-2416
45 schema:productId N513b09ee4fb549c9855320b7626dd4e4
46 N70567438b9384584a1f56902133a7776
47 N9987e839b7244413a7fee6053568296d
48 N99fbfc5f74754d91b56b7bd24445f3cd
49 Na6ff69b7f68c4dfab9c265bb64ec504a
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048672161
51 https://doi.org/10.1007/s12032-012-0211-2
52 schema:sdDatePublished 2019-04-11T02:11
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nbdc4c6ffa7f04d19adfca25f1c86e191
55 schema:url http://link.springer.com/10.1007%2Fs12032-012-0211-2
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N08429036bef2482490ed98718b67df3a schema:issueNumber 4
60 rdf:type schema:PublicationIssue
61 N094db75dbd744cd7963bd14556baf036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Disease-Free Survival
63 rdf:type schema:DefinedTerm
64 N2e0b46cb572f45c2bc7395b6f82acbc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Dexamethasone
66 rdf:type schema:DefinedTerm
67 N38282c13a6bd42888e4750715b3a0866 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Adult
69 rdf:type schema:DefinedTerm
70 N4ba110f342b74a33ae04d82c97954ab8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Antineoplastic Combined Chemotherapy Protocols
72 rdf:type schema:DefinedTerm
73 N4dabc9bc3bc44e36b5f78036eb5f08c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Male
75 rdf:type schema:DefinedTerm
76 N4ed7b348d9c14968a107ce77018e8811 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Aged
78 rdf:type schema:DefinedTerm
79 N513b09ee4fb549c9855320b7626dd4e4 schema:name pubmed_id
80 schema:value 22476761
81 rdf:type schema:PropertyValue
82 N55638aab395e42aab9eabfcfd3321a02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Recurrence
84 rdf:type schema:DefinedTerm
85 N61b510cdee58488dad5ce7b1aecfb115 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Middle Aged
87 rdf:type schema:DefinedTerm
88 N70567438b9384584a1f56902133a7776 schema:name readcube_id
89 schema:value e7dd5c28e14ce6994240f0579d320f4c64ba1715c07a3bf6a4e0983c4ed7906f
90 rdf:type schema:PropertyValue
91 N912e9577004b442c88a48f8dc0e82aa4 schema:volumeNumber 29
92 rdf:type schema:PublicationVolume
93 N94e0eaaf70d04d4792c2a46ddc98722b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antibodies, Monoclonal, Murine-Derived
95 rdf:type schema:DefinedTerm
96 N9987e839b7244413a7fee6053568296d schema:name doi
97 schema:value 10.1007/s12032-012-0211-2
98 rdf:type schema:PropertyValue
99 N99fbfc5f74754d91b56b7bd24445f3cd schema:name dimensions_id
100 schema:value pub.1048672161
101 rdf:type schema:PropertyValue
102 N9dad7e421b2a415cbb1883a653e83f1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Humans
104 rdf:type schema:DefinedTerm
105 Na6ff69b7f68c4dfab9c265bb64ec504a schema:name nlm_unique_id
106 schema:value 9435512
107 rdf:type schema:PropertyValue
108 Na836484be1ef4971ba571bfe66a89066 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Adolescent
110 rdf:type schema:DefinedTerm
111 Nb09feada92ec47efaab454740bd13888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Rituximab
113 rdf:type schema:DefinedTerm
114 Nb6c87c2839f4411f9dc97f63b3bdd16f rdf:first sg:person.01372344523.47
115 rdf:rest Nc45236ce92564327b635060160e56c04
116 Nbdc4c6ffa7f04d19adfca25f1c86e191 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 Nc45236ce92564327b635060160e56c04 rdf:first sg:person.0601034665.62
119 rdf:rest rdf:nil
120 Ndb5ca55c8f1547caa8040be388387905 rdf:first sg:person.0772057424.91
121 rdf:rest Nb6c87c2839f4411f9dc97f63b3bdd16f
122 Nf23216c1e99c4151ab37a308540bbbfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Lymphoma, B-Cell
124 rdf:type schema:DefinedTerm
125 Nfa70c05531b24ab0a2ef7d3059a2a206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Female
127 rdf:type schema:DefinedTerm
128 Nfc8825c4593041f8a866946d38fd49c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Deoxycytidine
130 rdf:type schema:DefinedTerm
131 Nff6bb8f557494191be897ea25ee70483 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cisplatin
133 rdf:type schema:DefinedTerm
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
138 schema:name Oncology and Carcinogenesis
139 rdf:type schema:DefinedTerm
140 sg:journal.1094524 schema:issn 1357-0560
141 1559-131X
142 schema:name Medical Oncology
143 rdf:type schema:Periodical
144 sg:person.01372344523.47 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
145 schema:familyName Wang
146 schema:givenName Hua-qing
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47
148 rdf:type schema:Person
149 sg:person.0601034665.62 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
150 schema:familyName Ba
151 schema:givenName Yi
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601034665.62
153 rdf:type schema:Person
154 sg:person.0772057424.91 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
155 schema:familyName Hou
156 schema:givenName Yun
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772057424.91
158 rdf:type schema:Person
159 sg:pub.10.1007/s12185-010-0666-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041242014
160 https://doi.org/10.1007/s12185-010-0666-x
161 rdf:type schema:CreativeWork
162 sg:pub.10.1023/a:1008294725992 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000992968
163 https://doi.org/10.1023/a:1008294725992
164 rdf:type schema:CreativeWork
165 https://app.dimensions.ai/details/publication/pub.1083106286 schema:CreativeWork
166 https://app.dimensions.ai/details/publication/pub.1083347691 schema:CreativeWork
167 https://doi.org/10.1046/j.1365-2141.2003.04226.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010001288
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1093/annonc/mdh093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020799712
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1093/annonc/mdm133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030304185
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1159/000077995 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042104091
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1182/blood-2004-08-3175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033024465
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1182/blood-2007-08-108415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052256184
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1200/jco.1999.17.12.3786 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074556142
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1200/jco.2000.18.21.3633 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074719574
182 rdf:type schema:CreativeWork
183 https://doi.org/10.3816/clml.2010.n.055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034335280
184 rdf:type schema:CreativeWork
185 https://doi.org/10.3904/kjim.2009.24.1.37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029979747
186 rdf:type schema:CreativeWork
187 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
188 schema:name Digestive Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
189 Lymphoma department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
190 Sino-US Center for Lymphoma and Leukemia, Tianjin, China
191 Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...